Painless lumps or swelling appear in 70 to 90 percent of testicular cancer cases at diagnosis. The disease accounts for 1 percent of male cancers in the United States while making up 5 percent of urologic tumors. Localized cases show a 99 percent five-year survival rate.
Key Takeaways
- The most common symptom is a painless lump or swelling in one testicle, reported in 70-90% of cases at diagnosis
- Scrotal pain or discomfort occurs in 27-46% of testicular cancer patients, often mimicking epididymitis
- Gynecomastia is present in 5-15% of patients with advanced testicular cancer due to hCG production by tumors
- In the United States, testicular cancer represents about 1% of all male cancers but accounts for 5% of urologic tumors with approximately 9,760 new cases expected in 2023
- Globally, around 74,000 new cases of testicular cancer were diagnosed in 2020, making it the 18th most common cancer worldwide
- The age-adjusted incidence rate of testicular cancer in the US is 5.9 per 100,000 men per year based on 2017-2021 data from SEER
- Orchiopexy for cryptorchidism before age 1 reduces cancer risk by 80% compared to no surgery
- Monthly testicular self-examination starting at age 15 is recommended by AUA for early detection
- Avoiding tobacco may reduce risk, as smokers have 1.4 times higher odds of testicular cancer
- Cryptorchidism (undescended testicle) increases testicular cancer risk by 3-5 times, affecting 3% of full-term male infants
- Family history of testicular cancer doubles the risk, with brothers of affected men having a 8-10 fold increased risk compared to 4-fold for sons or fathers
- Men with infertility issues have a 20% higher risk of developing testicular cancer, linked to abnormal semen parameters
- The 5-year relative survival rate for localized testicular cancer is 99%
- Overall 5-year survival for all stages of testicular cancer is 95% in the US
- For regional stage testicular cancer, 5-year survival is 96%, dropping to 73% for distant metastases
A painless testicular lump is the most common sign, and early diagnosis supports high survival rates.
Related reading
01 · Category
Diagnosis and Symptoms25 stats
01
The most common symptom is a painless lump or swelling in one testicle, reported in 70-90% of cases at diagnosis
02
Scrotal pain or discomfort occurs in 27-46% of testicular cancer patients, often mimicking epididymitis
03
Gynecomastia is present in 5-15% of patients with advanced testicular cancer due to hCG production by tumors
04
Dull ache or heaviness in the lower abdomen or scrotum is reported in 15-20% of cases
05
Hydrocele obscures the testicular mass in 10-20% of cases, requiring ultrasound for diagnosis
06
Elevated serum alpha-fetoprotein (AFP) is found in 50-70% of non-seminomatous germ cell tumors
07
Beta-hCG is elevated in 40-50% of seminomas and 60-80% of non-seminomas, aiding diagnosis
08
LDH levels are elevated in 60% of advanced disease, correlating with tumor burden
09
Testicular ultrasound shows hypoechoic masses in 95% of malignancies, with increased vascularity on Doppler
10
Radical inguinal orchiectomy is the gold standard for diagnosis and initial treatment in 99% of cases
11
Metastatic symptoms like back pain from retroperitoneal nodes occur in 10-15% at presentation
12
Breast tenderness from hCG elevation is noted in 7% of patients pre-diagnosis
13
Acute scrotal pain mimicking torsion occurs in 10% of testicular cancer presentations
14
Cough, dyspnea, or hemoptysis from pulmonary metastases in 5-10% of advanced cases
15
Neck mass from supraclavicular lymphadenopathy in 2-5% at diagnosis
16
Testicular self-exam detects 70% of cases early when performed monthly from puberty
17
Sudden testicular enlargement without pain in 80% of seminoma cases
18
Leg swelling from iliac vein compression in 3% with bulky retroperitoneal disease
19
LDH elevation >10x upper limit indicates poor prognosis in 80% of cases
20
AFP half-life post-orchiectomy <24 hours normalizes in compliant monitoring
21
MRI used in 5% equivocal ultrasound cases, sensitivity 95% for malignancy
22
PET-CT for seminoma post-chemo detects residual viable disease in 80% with FDG uptake
23
Fine-needle aspiration avoided due to 30% seeding risk
24
Bone scan only for symptoms or LDH>10x, positive in 15% advanced disease
25
Head CT for neurologic symptoms in 2% with brain mets at diagnosis
Interpretation
Diagnosis and Symptoms Interpretation
While you should never ignore a painless testicular lump—your best chance at a cure—the diagnostic journey is a masterclass in medical irony, where swelling can hide cancer, back pain can point to your groin, and sometimes the only clear symptom is a tender spot on your chest.
02 · Category
Epidemiology25 stats
01
In the United States, testicular cancer represents about 1% of all male cancers but accounts for 5% of urologic tumors with approximately 9,760 new cases expected in 2023
02
Globally, around 74,000 new cases of testicular cancer were diagnosed in 2020, making it the 18th most common cancer worldwide
03
The age-adjusted incidence rate of testicular cancer in the US is 5.9 per 100,000 men per year based on 2017-2021 data from SEER
04
Testicular cancer incidence is highest among men aged 15-44 years, with a peak incidence rate of 11.2 per 100,000 in the 25-29 age group in Europe
05
In the UK, there were 2,112 new testicular cancer cases in 2017-2019, representing 1% of all new cancer cases in males
06
White men have a 4-5 times higher incidence of testicular cancer compared to Black men in the US, with rates of 5.8 vs 1.0 per 100,000
07
Testicular cancer mortality has declined by 52% in the US from 1975 to 2020, from 1.0 to 0.5 per 100,000 men
08
In Australia, testicular cancer is the most common cancer in men aged 15-39, with 1,050 new cases in 2022
09
Nordic countries like Denmark have the highest incidence rates globally at 12.6 per 100,000 men
10
In Asia, testicular cancer incidence is low at 0.9 per 100,000, compared to 7.2 in Northern America
11
Seminomas account for 55% of all testicular germ cell tumors diagnosed in the US
12
The incidence of testicular cancer has increased by 56% in the UK since the early 1990s, from 4.5 to 7.0 per 100,000
13
Hispanic men in the US have seen a 78% increase in testicular cancer incidence from 1992-2015, higher than other groups
14
In 2020, testicular cancer caused 9,800 deaths worldwide, primarily in low-resource settings
15
The prevalence of testicular cancer survivors in the US is estimated at over 300,000 men living with a history of the disease
16
In Denmark, testicular cancer incidence rates rose from 5.4 to 12.6 per 100,000 between 1960-2015
17
African American men have the lowest incidence at 0.9 per 100,000 vs 6.2 for non-Hispanic whites
18
Testicular cancer accounts for 1.2% of all male cancers globally but 5% in young men 20-34 years
19
In Canada, 1,030 new cases expected in 2023, with incidence stable at 5.6 per 100,000
20
Embryonal carcinoma subtype comprises 20-25% of non-seminomas, often aggressive
21
Bilateral testicular cancer occurs in 1-5% of cases, higher in genetic syndromes
22
Age-specific rate peaks at 15.6 per 100,000 in US men aged 30-34
23
In Japan, incidence is 0.5 per 100,000, attributed to genetic and environmental factors
24
Mortality-to-incidence ratio is 0.13 globally, better in high-income countries at 0.05
25
Over 50,000 testicular cancer survivors in the UK as of 2020
Interpretation
Epidemiology Interpretation
While testicular cancer is relatively rare overall, it’s a dominant threat to young men’s health in many countries, proving that this small-organ cancer punches well above its weight class, yet its high cure rate offers a serious reminder that vigilance and treatment save lives.
03 · Category
Prevention10 stats
01
Orchiopexy for cryptorchidism before age 1 reduces cancer risk by 80% compared to no surgery
02
Monthly testicular self-examination starting at age 15 is recommended by AUA for early detection
03
Avoiding tobacco may reduce risk, as smokers have 1.4 times higher odds of testicular cancer
04
No routine screening for average-risk men, but self-exam education reduces late-stage diagnosis by 30%
05
Vaccination against mumps in childhood prevents orchitis, potentially lowering risk by 20-30%
06
Limiting endocrine disruptor exposure in plastics (BPA) may decrease risk, per animal models showing 2-fold increase
07
Genetic counseling for families with multiple cases identifies KITLG variants increasing risk 3-fold
08
Early orchidopexy and monitoring for boys with cryptorchidism detects ITGCN early in 5-10%
09
Public awareness campaigns have increased early detection, reducing advanced disease from 25% to 15% in UK
10
Sperm banking pre-treatment prevents infertility in 50% of survivors who desire children
Interpretation
Prevention Interpretation
If you want to keep your future options open, the takeaway is: treat your testicles like a priceless, slightly fragile heirloom by descending them early, examining them monthly, avoiding toxins, banking some swimmers if needed, and for heaven's sake, don't smoke.
More related reading
04 · Category
Risk Factors25 stats
01
Cryptorchidism (undescended testicle) increases testicular cancer risk by 3-5 times, affecting 3% of full-term male infants
02
Family history of testicular cancer doubles the risk, with brothers of affected men having a 8-10 fold increased risk compared to 4-fold for sons or fathers
03
Men with infertility issues have a 20% higher risk of developing testicular cancer, linked to abnormal semen parameters
04
Previous testicular cancer in one testicle increases risk in the other by 12-fold, or 2-5% lifetime risk
05
HIV infection is associated with a 3-5 fold increased risk of testicular seminoma due to immune dysregulation
06
White race/ethnicity confers a higher risk, with US white men having incidence 4.5 times higher than black men
07
Intratubular germ cell neoplasia (ITGCN), or testicular intraepithelial neoplasia, precedes nearly all invasive germ cell tumors and is found in 5% of infertile men
08
Maternal estrogen exposure in utero, such as from hormone treatments, may increase risk by 2-3 fold
09
History of orchidopexy for cryptorchidism before age 10 reduces risk by 50% compared to later correction
10
Klinefelter syndrome (47,XXY) increases risk 3-6 fold due to hypogonadism and germ cell abnormalities
11
Cannabis use is linked to a 1.62 odds ratio for non-seminoma testicular cancer in heavy users under 35
12
Occupational exposure to pesticides or endocrine disruptors increases risk by 1.5-2 fold in agricultural workers
13
Atrophic testes have a 10-40 fold increased risk of malignancy compared to normal testes
14
Genetic factors like isochromosome 12p are present in 80-90% of testicular germ cell tumors
15
Personal history of testicular cancer increases contralateral risk to 2.5-4.8%
16
Twin studies show heritability of 38-48% for familial testicular cancer
17
Hypospadias associated with 2-3 fold risk increase due to shared embryologic defects
18
Obesity (BMI >30) linked to 28% reduced risk paradoxically, unlike other cancers
19
Leprosy patients have 4-fold higher seminoma risk from immune factors
20
Pesticide exposure in fathers before conception increases offspring risk by 1.5 fold
21
No proven link to cell phone radiation despite case reports
22
Physical activity >5 hours/week reduces risk by 24% in cohort studies
23
Varicocele surgery history shows no increased risk, unlike prior orchitis
24
Mumps orchitis post-puberty increases risk 7-fold
25
Latex allergy weakly associated (OR 1.5) via cross-reactivity hypotheses
Interpretation
Risk Factors Interpretation
While some men are born with hidden risks and others acquire them through life, it’s clear that testicular cancer often emerges from a tangled intersection of unlucky genetics, developmental quirks, environmental exposures, and immune mysteries.
05 · Category
Survival and Prognosis23 stats
01
The 5-year relative survival rate for localized testicular cancer is 99%
02
Overall 5-year survival for all stages of testicular cancer is 95% in the US
03
For regional stage testicular cancer, 5-year survival is 96%, dropping to 73% for distant metastases
04
Cure rates exceed 90% even for metastatic disease with cisplatin-based chemotherapy
05
Seminoma stage I has a 98-99% 5-year disease-free survival with surveillance or radiation
06
Non-seminoma good-risk metastatic disease has 92% 5-year survival per IGCCCG classification
07
Long-term survival after relapse post-chemotherapy is 80% with salvage high-dose chemotherapy
08
Secondary malignancies occur in 1.4-7% of survivors within 25 years, higher with platinum chemo
09
Cardiovascular disease risk is 1.5-2 fold higher in testicular cancer survivors due to chemotherapy
10
Neurologic toxicity from etoposide in BEP regimen affects 20-30% long-term survivors
11
10-year overall survival for stage III seminoma is 82%
12
Fertility preservation success: 70-90% of men bank sperm successfully pre-treatment
13
Contralateral testis cancer risk post-orchiectomy is 1.8-5%, warranting lifelong self-exam
14
Quality of life returns to baseline in 80% of survivors 2 years post-treatment
15
15-year survival for good-risk metastatic GCT is 91% with modern therapy
16
Late relapse >2 years occurs in 3% non-seminoma, requiring surgical salvage
17
Hearing loss from cisplatin affects 20-40% survivors, dose-dependent >400mg/m2
18
Raynaud phenomenon in 20-30% post-cisplatin, managed with calcium/magnesium
19
Hypogonadism in 10-30% long-term survivors, higher post-chemo
20
Overall survival improvement from 83% in 1975 to 95% in 2020 due to BEP regimen
21
Stage IS (persistent markers) cured with chemo in 90-95%
22
Growing teratoma syndrome post-chemo in 2-4% non-seminoma, treated surgically
23
Suicide risk 1.8-fold higher in survivors due to psychological burden
Interpretation
Survival and Prognosis Interpretation
While the survival numbers are brilliantly high, the full story of beating testicular cancer is a lifelong balancing act between celebrating a cure and managing the significant side effects that can come with it.
06 · Category
Treatment21 stats
01
Radical inguinal orchiectomy via high inguinal incision is performed in 95% of suspected cases for diagnosis and staging
02
Surveillance is recommended for stage I seminoma after orchiectomy, with relapse rate of 15-20%
03
BEP chemotherapy (bleomycin, etoposide, cisplatin) for 3 cycles cures 99% of good-risk metastatic disease
04
Retroperitoneal lymph node dissection (RPLND) is standard for stage II non-seminoma, reducing relapse to 3%
05
Single-agent carboplatin with radiation for stage I seminoma reduces relapse to 3.7% vs surveillance
06
High-dose chemotherapy with autologous stem cell transplant for relapsed disease achieves 50-60% cure
07
Testicular prosthesis implantation occurs in 60-80% of patients post-orchiectomy for cosmetic reasons
08
Adjuvant chemotherapy with 1 cycle BEP for high-risk stage I non-seminoma reduces relapse from 50% to 1-3%
09
Radiation therapy for seminoma stage IIA delivers 30-36 Gy to para-aortic nodes, curing 90-95%
10
VIP regimen (VIP: vinblastine/ifosfamide/cisplatin) used for poor-risk GCT with 50% response rate
11
Nerve-sparing RPLND preserves antegrade ejaculation in 90% of patients
12
Active surveillance compliance is 75-85%, with CT scans every 3-4 months initially
13
EP x 4 cycles alternative to BEP for bleomycin-intolerant patients, similar efficacy 92%
14
Risk-adapted RPLND templates reduce morbidity while covering 95% nodal sites
15
Adjuvant radiation omitted in stage I low-risk seminoma per EAU guidelines, surveillance preferred
16
TIP regimen (paclitaxel/ifosfamide/cisplatin) for salvage yields 60% response in first relapse
17
Primary RPLND for stage IS non-seminoma in select cases, avoiding chemo
18
De-escalated IGCCCG poor-risk trials show 75% PFS with novel agents
19
Sperm DNA fragmentation low post-orchiectomy but rises 20% post-chemo
20
Robot-assisted RPLND emerging with 90% ejaculation preservation, shorter stay
21
2 cycles BEP equivalent to 1 cycle + RPLND for high-risk stage I NSGCT, relapse 2%
Interpretation
Treatment Interpretation
We've become remarkably adept at preserving both life and quality of life, refining an arsenal from vigilant waiting to precision strikes so that even though the journey begins with losing a testicle in most cases, the path that follows offers a menu of highly effective, increasingly tailored options to cure the cancer while protecting fertility, function, and peace of mind.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
David Sutherland. (2026, February 13). Testicular Cancer Statistics. Gitnux. https://gitnux.org/testicular-cancer-statistics
MLA
David Sutherland. "Testicular Cancer Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/testicular-cancer-statistics.
Chicago
David Sutherland. 2026. "Testicular Cancer Statistics." Gitnux. https://gitnux.org/testicular-cancer-statistics.
Sources & references
16 datasets cited across this report · attribution is report-level